Almac Sciences, a member of the Almac Group, is investing £500,000 in NMR instrumentation at its global Headquarters, Craigavon, UK, marking an over £900,000 total investment in nuclear magnetic resonance (NMR) technology for the organization since 2018.
 
High-resolution NMR is a key enabling technology that delivers advanced characterization and purity assessment abilities in line with regulatory requirements. The service helps support drug substance (API) and drug product development programs, from early phase to commercialization.
 
The investment includes the addition of a second 500MHz NMR system, which has been added to further expand the current service offerings within of Almac Sciences’ cGMP facility. This will boost Almac’s current NMR testing service, while also increasing through-put, capacity, and speed to enhance efficiency and turnaround times.
 
The second 500MHz NMR instrument installation at Almac combines Bruker’s Avance Neo platform with a Prodigy Cryoprobe. This improves capacity to analyze nuclei from 15N to 31P to high sensitivity and resolution, in addition to the running of 2D and quantitative NMR experiments. It also provides additional security for urgent analyses, additional processing capabilities, and superior data integrity controls to ensure increasing regulatory compliance needs are met.
 
Dr. John Malone, Analytical Manager, Almac Sciences said, “The additional NMR technology installation in our cGMP lab allows increased security, flexibility and capacity enabling us to provide an enhanced service to our clients.”